Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2026-04-28 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 1% confidence The document is titled “Delårsrapport kv 1 2026” (Interim Report Q1 2026) and includes detailed financial statements (income statement, cash flow, balance sheet items), operational and CEO/CFO commentary, pipeline updates, and future reporting calendar – all typical components of a quarterly interim report. It is not simply an announcement of a report (it contains the full report content), nor an earnings release summary, but a comprehensive interim financial report. Therefore, it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-28 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 1% confidence The document is titled “Interim Report Q1 2026” and contains detailed financial summaries (income, cash flow, EPS), operational highlights, CEO comments, segment-level tables, notes on discontinued operations, and financial statements for the quarter ended March 31, 2026. It is a comprehensive quarterly report, not merely an announcement or a brief release. Therefore, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-04-28 English
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory press release in Swedish announcing the updated number of outstanding shares and voting rights in Orexo AB as of March 31, 2026, including details on the conversion of C-shares to ordinary shares. This constitutes a change in the company’s share capital structure (share class conversion) and falls under announcements of share issues or capital changes. Therefore, it is classified as a Share Issue/Capital Change (SHA) filing.
2026-03-31 Swedish
Number of shares and votes in Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the total number of shares and votes following the conversion of Class C shares into ordinary shares. This conversion represents a capital structure change rather than an insider transaction or dividend notice. It fits the definition of a Share Issue/Capital Change announcement (SHA).
2026-03-31 English
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 1% confidence FY 2025
2026-03-27 Swedish
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 1% confidence The document is a Swedish flagging notice published by the Finansinspektionen showing Morgan Stanley’s change in holdings of Orexo AB ordinary shares crossing statutory thresholds. It provides pre- and post-transaction share counts, voting rights percentages, and the legal basis for notification under LHF (the Swedish Act on Trading in Financial Instruments). This is a major shareholding notification and aligns exactly with the MRQ category.
2026-03-24 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.